Cephalon CEPH
-
New Morningstar Analyst Report - Teva Pharmaceutical Industries, Ltd.
… opinion. Teva's acquisition of Cephalon and the appointment of Jeremy Levin ..... Gerard Van Odijk, and former CEO of Cephalon Kevin Buchi as the vice president ..... Bolstered by its acquisition of Cephalon , Teva also plans to expand its innovative …
-
Teva Pharmaceuticals' Disappointing Results
… expanding into the branded proprietary drug market. To build out its branded product line, Teva recently purchased Cephalon ( CEPH ) for $6.5 billion. The company is also in the midst of a leadership change. Shlomo Yanai left the CEO position …
-
Finding Good Pharma Stocks
… To offset the expiration, Teva bought two companies in 2011: Taiyo, the third largest generics company in Japan, and Cephalon , a global biotech company. These acquisitions will add to Teva’s earnings this year. In addition, Teva entered …
-
Teva's Revenue Growth Falls Short on European Pricing Pressure
… markets posted 30% growth. Boosted by the Cephalon acquisition, growth of 54% in Teva ..... into our forecast. The integration of Cephalon appears on track, and Teva's operating ..... realize synergies from the integration of Cephalon .
-
New Morningstar Analyst Report for Valeant Pharmaceuticals International Inc.
… made its hostile takeover offer for Cephalon , it planned to finance the $5 ..... debt load, and as we saw with its Cephalon bid, Valeant is willing to significantly ..... its Biovail merger and its bid for Cephalon , but it prefers to acquire small …
-
Warner Chilcott Seeks Strategic Alternatives, but We See Limited Pool of Buyers
… think it could make the deal work if it were really interested. However, the firm already has its hands full integrating Cephalon and may not be interested in another large acquisition right now. Given the complexities of its portfolio, we think …
-
Valeant: Zovirax, New Acquisitions Are Big Money-Spinners
… said that marketed products are more valuable than pipeline products. Pearson announced it during the bid to takeover Cephalon , which was later acquired by Teva Pharmaceuticals ( TEVA ). Valeant has made other similar bids these past years. Its …
-
Top Biotech Acquisition Candidates… the typical big pharma biotech deal that we've seen. Generics leader Teva has spent just over $6 billion to acquire Cephalon , which really helped to round out its specialty pharma and branded business. Migliore : But it does look like things …
seen. Generics leader Teva has spent just over $6 billion to acquire Cephalon , which really helped to round out its specialty pharma and branded business. Migliore : But it does look like things are -
Pharma Spin-Off Should Unlock Value of Covidien's Well-Positioned Device Business
… patent loss for Endo ENDP, Cardiolite's patent loss for the former Bristol BMY imaging business, loss of Provigil for Cephalon (now part of Teva TEVA), and reactor concerns with Nordion NDZ. While Covidien's pharma business carries margins …
-
More on Teva (TEVA) Q4: Last year's purchase of Cephalon helps boost adjusted net profit 23% to $1.4B and revenues from brand-name drugs by 68% to $2.3B. Sales of Copaxone, which faces competition ...
More on Teva ( TEVA ) Q4 : Last year's purchase of Cephalon helps boost adjusted net profit 23% to $1.4B and revenues from brand-name drugs by 68% to $2.3B. Sales of Copaxone, which faces competition from newer treatments, +11% to $927M. Post your comment!